
#### 2002 LEGISLATIVE FORUM

#### **December 10, 2002**

Rx For Washington: How Can Washington State Keep Prescription Drug Costs Down?

Dr. Art Zoloth Northwest Pharmacy Services azoloth@att.net




Wight I suggest the most expensive wine and the most expensive dinner?"

Might I suggest the most expensive wine and the most expensive dinner?

## Percent change in spending

Contribution of Prescription Drugs and Other Health Services to Change



## No opposing voice to promotion

- Manufacturers control the flow of information to the media, providers patients and policy-makers
- FDA is designated protector of the public interest, but marginalized and prohibited from expressing an opinion
- Marketing v. Science



## ELEMENTARY WATSON! WE DISCOVER THE TRUE MESSAGE OF THE STATE ELECTION.

PUBLIC TRUST

THE SEATTLE TIMES

## The American Way

- United Kingdom; death is imminent
- Canada; death is inevitable
- California; death is optional

#### Lack of Market Forces

- He/she that orders the prescription is usually at no financial risk.
- He/she that receives the prescription usually has no choice.
- With some exceptions, those that pay usually have very little understanding of the process or outcome.

## **Conflicting Demands**

Consumers want unfettered access to the newest, most promising drugs, and they want to pay as little as possible for them regardless of the cost to the overall healthcare system.

## **Conflicting Demands**

- Providers want little or no controls over what is ordered and dispensed.
- The "multiple formulary" issue

## Physician's View

"If I have 10 minutes to see a patient, I'm not, going to spend half that time looking through a plan formulary to see which drugs are covered".

## **Conflicting Demands**

Payers want health plans to hold the line on costs.

## **Conflicting Demands**

Drug manufacturers/Stockholders want to maximize profits

## Pricing Mystery?

- Introduction at premium prices, increased as drugs become accepted
- As new competition enters the market often prices continue to increase
- As generics inter the market, branded equivalents increase in price

## **Policy Options**

Price Controls

Subsidies

Buying Smarter/Enhancing Quality

#### **Price Controls**

- International cost shifting
- We are the only industrialized country without some form of cost constraint

Cost controls too blunt an instrument and politically DOA

#### **Subsidies**

- Means-tested or other criteria for participation.
- Limited population
- Requires tax funded support

## Buying Smarter/Enhancing quality

- Dysfunctional Market
- Creating Competition
- Educating providers/consumers
- Drive Market Share

#### Pharmaceutical Industry Agenda

"...influence into legislative victories"

- <u>Control</u> of any <u>Medicare Prescription Coverage</u> legislation.
- Oppose any price control legislation
- Oppose any federal/state effort to establish a list of preferred drugs.
- Oppose legislation that would speed the approval and marketing of generic drugs.

#### Pharmaceutical Industry Agenda

#### "Influence into legislative victories"

- Oppose legislation making it easier for consumers, pharmacist and wholesalers to import drugs from Canada.
- Oppose Congressional efforts to limit or discourage drug advertising directly to consumers.
- Support legislation that would limit damages in lawsuits filed by consumers that may have been injured by drugs.

New York Times November 21, 2002

## Drug Access and Quality Prescribing Act

Public/Private Sector Partnership

#### **Problem**

- Segments of the population are experiencing financial barriers to accessing prescription drugs
  - Elderly, and Disabled/chronically ill
  - Employers
  - Employees with employer-sponsored prescription benefits (shifting costs via increased co-pays)
  - Persons covered by State programs
  - Individuals
  - Uninsured

## Problem (continued)

- Budgets are straining under increased drug costs
  - State
  - Individual and family
  - Businesses



"I'm going to prescribe something that works like aspirin but costs much, much more."

### Problem (continued)

- Cost effectiveness lacking in prescription drug choice
  - □ Therapeutic equivalence within drug classes
    - □ Anti-Inflammatory Drugs − Ibuprofen, Naproxin, Celebrex,
    - □ Cholesterol Reducing Drugs Zocor, Lescol, Lipitor
    - □ Anti-Depression (SSRI's) Celexa, Prozac, Zoloft
  - Many new drugs being approved are "me too" drugs
    - □ Proton Pump Inhibitors Prilosec v. Nexium
    - □ Non-sedating Antihistamines Claritin v. Clarinex

## Problem (continued)


- Prescription drug decisions driven by marketing and advertising, not by scientific evidence
  - Brand use vs. generics without evidence of brand superiority
  - Patient demand for drugs based on direct-to-consumer advertising
  - Inappropriate (or with inadequate indications) use of brand name pharmaceuticals

#### **Solution**

#### Key Features of Act:

- Public/private partnership
- Voluntary participation of private sector
- Independent board with no conflicts of interest
- Value-driven, evidence-based prescription drug list (most effective, least costly drugs)
- Clinically managed (Physicians/Pharmacists)
- Not single payer Contracting Unit only negotiates the price of drugs, it does not buy them

#### Drug Access and Quality Prescribing Act




#### Purchaser/Provider Board

- Independent
- Members appointed by Governor
- Composed of physicians, pharmacists, business community, health plans, state agencies, unions and consumer groups
- No conflicts of interest with pharmaceutical companies
- Appoints and oversees activities of the Pharmacy and Therapeutics Committee and the Contracting Unit

## Public/Private Sector Partnership

#### Board Composition —



#### Pharmacy and Therapeutics Committee

- Appointed by Board
- Comprised of physicians and pharmacists
- Seeks input from specialists as needed
- Responsible for:
  - Quality Assurance
  - Preferred Drug List
  - Drug Utilization Review
  - Provider/consumer education

## **Preferred Drug List**

- Guiding principles are quality and value
- Unbiased
- Developed using standardized evidence-based research methods
- Reliance on reviews from established evidence-based practice centers
- Process for appeals and exceptions

## **Quality Assurance**

- Includes Drug Utilization Review and provider/consumer education
- Drug Utilization Review:
  - Based on electronically-gathered information
  - Reviews of provider prescribing patterns to ensure appropriate utilization of Preferred Drug List
  - Education and re-education of providers regarding
     Preferred Drug List and prescribing practices
- Consumer education

## **Contracting Unit**

- Appointed and managed by Board
- Authority to negotiate and award contracts
- Contracts with pharmaceutical manufactures and distributors for price of drugs on Preferred Drug List
- Enters into agreements with entities that participate in program

### Health Plans (private sector)

- Voluntary participation
- Benefit design continues to be plan-managed
- Opportunity to contribute to and share in Preferred Drug List
- Opportunity to share in contracts with pharmaceutical manufacturers (market share)
- Opportunity to decrease costs associated with formulary management

## Deep Throat / Watergate

## "Follow the money"

# I never worry about action, but only inaction.

-Sir Winston Churchill